<DOC>
	<DOCNO>NCT00103051</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Gefitinib may stop growth tumor cell block enzymes need cell growth . Giving gemcitabine cisplatin together gefitinib surgery may shrink tumor remove . PURPOSE : This phase II trial study well give gemcitabine cisplatin together gefitinib work treat patient undergo surgery stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Gefitinib Treating Patients Who Are Undergoing Surgery Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine therapeutic activity neoadjuvant induction therapy comprise gemcitabine , cisplatin , gefitinib patient stage IIIA non-small cell lung cancer undergo surgery . Secondary - Determine safety profile regimen patient . - Determine stage downsize complete resectability rate patient progressive disease undergo surgery treatment regimen . OUTLINE : This open-label , nonrandomized , multicenter study . Patients receive induction therapy comprise gemcitabine IV 30 minute day 1 , 8 , 22 , 29 , 43 , 50 ; cisplatin IV 3-6 hour day 2 , 23 , 44 ; oral gefitinib daily day 51-79 . Treatment continue absence disease progression unacceptable toxicity . Within 2-7 day completion induction therapy , patient progressive disease undergo tumor resection . After completion study treatment , patient follow least every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 55 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary nonsmall cell lung cancer ( NSCLC ) Clinical stage IIIA chest CT scan Unresectable N2 disease mediastinoscopy , mediastinotomy , thoracotomy , videoassisted thoracic surgery Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Planning undergo lobectomy pneumonectomy induction therapy No N3 metastatic disease physical exam , thoracic CT scan , bone scan , CT scan ultrasound liver adrenal gland No pleural pericardial effusion No superior vena cava syndrome No diffuse interstitial pulmonary fibrosis No sign symptom CNS involvement PATIENT CHARACTERISTICS : Age Over 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic AST ALT ≤ 1.5 time upper limit normal ( ULN ) Bilirubin normal Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 1.25 time ULN Creatinine clearance ≥ 60 mL/min Cardiovascular No medically uncontrolled congestive heart failure angina pectoris No uncontrolled hypertension arrhythmia No myocardial infarction within past year Other Not pregnant nursing Fertile patient must use effective contraception Physically mentally fit receive gemcitabine cisplatincontaining chemotherapy Physiologically fit undergo surgery No uncontrolled , active infection require IV antibiotic No history hypersensitivity gefitinib excipients No motor sensory neurotoxicity ≥ grade 2 No primary malignancy within past 5 year except carcinoma situ cervix adequately treat basal cell skin cancer No prior melanoma , breast cancer , renal cell cancer No psychological , familial , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy NSCLC No concurrent chemotherapy Endocrine therapy No concurrent antiestrogen therapy Concurrent replacement steroid antiemetic steroid allow Radiotherapy No prior radiotherapy NSCLC Surgery See Disease Characteristics No prior surgery NSCLC Other More 1 month since prior concurrent investigational agent No prior therapy NSCLC No concurrent CYP3A4 inducer , include follow : Phenytoin Carbamazepine Rifampin Barbiturates ( e.g. , phenobarbital ) Hypericum perforatum ( St. John 's wort ) No concurrent systemic retinoids No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>